11C-PS13 clinical trials
How each study uses 11C-PS13 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 11C-PS13 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- 11C-PS13
- 3
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Often tested with
Tested in the same studies.
(11C)-MC1 (2)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses 11C-PS13 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- PET Imaging of Cyclooxygenases in Neurodegenerative Brain DiseaseRecruitingPhase 1National Institute of Mental Health (NIMH)NCT04396873Written as 11C-PS13
- PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)RecruitingPhase 1National Institute of Mental Health (NIMH)NCT04582916Written as 11CPS13
- PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)RecruitingPhase 1National Institute of Mental Health (NIMH)NCT06920628Written as 11C-PS13
- PET Imaging of Cyclooxygenase in Multiple SclerosisTerminatedPhase 2National Institute of Mental Health (NIMH)NCT05062083Written as 11C-PS13
Codes
What other systems call 11C-PS13 · ClinicalTrials.gg INT001204
- MeSH (NLM) C00065453011C-PS13One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654530 | 11C-PS13 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.